43 results
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
27 Sep 23
Regulation FD Disclosure
4:43pm
as needed.
Graft-versus-Host Disease
Acute and chronic GvHD, including life-threatening and fatal cases, occurred following treatment with OMISIRGE … ). Chronic GvHD occurred in 35% (41/117) of patients. Acute GvHD manifests as maculopapular rash, gastrointestinal symptoms, and elevated bilirubin. Patients
8-K
EX-99.1
czchwq4p6 j3c1six
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
DEF 14A
xdhmmu6
22 Jun 22
Definitive proxy
4:22pm
PRE 14A
jf5 x84r6ddp9x
10 Jun 22
Preliminary proxy
4:25pm
10-Q
40l46
12 May 22
Quarterly report
7:42am
8-K
EX-99.1
wd50lga73fpkqb c3
10 May 22
Gamida Cell Reports First Quarter 2022 Financial Results
7:30am
10-K
ecfi mw1zox50
24 Mar 22
Annual report
7:30am
6-K
EX-99.1
pz23bc146ukvnn
15 Nov 21
Gamida Cell Reports Third Quarter 2021 Financial Results
7:29am
6-K
EX-99.1
vs4vyeex
11 May 21
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
8:28am
6-K
EX-99.1
xzz qcw0yul94i9v
9 Mar 21
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
4:08pm